文献速递其他结缔组织病类风湿关节炎系统性红斑狼疮

结缔组织病相关间质性肺病进行性纤维化机制

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
PubMed 文献 · Ann Rheum Dis · 2020-10-09

综述探讨结缔组织病相关间质性肺病(CTD-ILD)中驱动肺纤维化的生物学与遗传机制。尼达尼布在SSc-ILD及多种进行性表型纤维化ILD中显示疗效与安全性,吡非尼酮II期数据提示可能对进行性表型纤维化ILD有活性。作者指出,进行性纤维化表型可能源于共同的基础病理生理纤维化机制,但机制共性与差异证据仍匮乏。

要点

  • CTD-ILD可表现为进行性纤维化表型,导致肺功能下降、呼吸症状恶化及死亡率升高。
  • 尼达尼布在SSc-ILD及多种进行性表型纤维化ILD中显示疗效与安全性。
  • 进行性纤维化表型可能源于共同纤维化机制,但机制共性与差异证据不足。

核心结论

  • 无论ILD原始临床诊断如何,进行性纤维化表型可能源于共同的基础病理生理纤维化机制,涉及尼达尼布靶点相关通路及可能吡非尼酮相关通路。
  • 目前对进行性表型ILD之间机制共性与差异所知甚少,需进一步研究以进行性表型为目标人群提供依据。

研究设计与样本

  • 综述,探讨驱动纤维化的生物学与遗传机制,并识别进一步研究所需的缺失证据。

主要发现

  • 临床 distinct 的ILD患者(无论是否CTD相关)可表现出共同临床疾病行为:肺功能下降、呼吸症状恶化及更高死亡率,归因于肺部进行性纤维化。
  • 尼达尼布在IPF、SSc-ILD及包括CTD相关在内的多种进行性表型纤维化ILD中显示疗效与安全性。
  • 吡非尼酮II期研究数据提示,除IPF已知疗效外,可能对其他进行性表型纤维化ILD也有活性,其作用机制不同但 largely unknown。

临床怎么用

  • 关注CTD-ILD患者进行性纤维化表型的识别,该表型与肺功能下降、症状恶化及死亡率升高相关。
  • 尼达尼布可用于SSc-ILD及多种进行性表型纤维化ILD(包括CTD相关),基于其显示的疗效与安全性。

局限性

  • 尽管临床研究提供早期概念验证,但对进行性表型ILD之间机制共性与差异所知甚少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and connective tissue disease (CTD-ILD), such as rheumatoid arthritis-ILD and systemic sclerosis (SSc-ILD). Patients with clinically distinct ILDs, whether CTD-related or not, can exhibit a pattern of common clinical disease behaviour (declining lung function, worsening respiratory symptoms and higher mortality), attributable to progressive fibrosis in the lungs. In recent years, the tyrosine kinase inhibitor nintedanib has demonstrated efficacy and safety in idiopathic pulmonary fibrosis (IPF), SSc-ILD and a broad range of other fibrosing ILDs with a progressive phenotype, including those associated with CTDs. Data from phase II studies also suggest that pirfenidone, which has a different-yet largely unknown-mechanism of action, may also have activity in other fibrosing ILDs with a progressive phenotype, in addition to its known efficacy in IPF. Collectively, these studies add weight to the hypothesis that, irrespective of the original clinical diagnosis of ILD, a progressive fibrosing phenotype may arise from common, underlying pathophysiological mechanisms of fibrosis involving pathways associated with the targets of nintedanib and, potentially, pirfenidone. However, despite the early proof of concept provided by these clinical studies, very little is known about the mechanistic commonalities and differences between ILDs with a progressive phenotype. In this review, we explore the biological and genetic mechanisms that drive fibrosis, and identify the missing evidence needed to provide the rationale for further studies that use the progressive phenotype as a target population.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2020. PMID: 33037004. doi:10.1136/annrheumdis-2020-217230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。